KYMR Kymera Therapeutics, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
23:24
Jul 02
Jul 02
The tweet details the merger timeline between AbbVie and Apogee with no author position, noting that the atopic dermatitis space remains of interest to biopharma.
10:54
Jun 26
Jun 26
Author asserts KYMR appears more valuable than APGE on a relative valuation basis, in context of APGE's $11B acquisition.
MED
00:32
Jun 23
Jun 23
The author mocks a corporate slide from Kymera Therapeutics for a poor before-and-after comparison, expressing skepticism but not a trade position.
LOW
00:32
Jun 23
Jun 23
The tweet reports market cap increases for KYMR and NKTR without expressing a personal position or forward-looking trade view.
LOW
13:13
Jun 21
Jun 21
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A timing framework shows this is the window where acquirers with pre-committed capital execute; sector M&A wave across radiopharmaceuticals, MASH, IBD, and obesity validates the pattern is active.
MED
00:55
Jun 21
Jun 21
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom, but it is a factual research summary without explicit author positions or forward calls.
LOW
15:42
Jun 19
Jun 19
Co-mentioned as part of atopic dermatitis basket expected to benefit from the APGE M&A deal read-through; no specific thesis beyond sector lift.
MED
14:34
Jun 19
Jun 19
Author reviews merger documents and identifies read-through targets for potential takeovers, but does not state personal positions or forward calls.
00:16
Jun 15
Jun 15
Named as potential public AtD takeout candidates if BP shifts acquisition strategy from privates to public companies; author frames as speculative question.
MED
19:10
Jan 04
Jan 04
KYMR cited as a competitive threat capable of displacing CRVS more than injectable biologics; no direct bullish position stated by author.
LOW
About KYMR Analyst Coverage
Buzzberg tracks KYMR (Kymera Therapeutics, Inc.) across 2 sources. 1 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (10%). 10 total trade ideas tracked. Latest voices: seedy19tron, A May MD.